ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2015
PET imaging of tenascin-C with a radiolabeled single-stranded DNA aptamer.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 82 citations in OpenAlex.
- Tumour Microenvironment-Informed Radiotheranostics: Why and How Nuclear Medicine Could Advance Precision Oncology in the Decade Ahead.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Innovative aptamer approaches in glial tumor diagnostics and therapy: Progress and future directions.Molecular therapy. Nucleic acids · 2025Review
- The Future of PET Imaging in Multiple Sclerosis: Characterisation of Individual White Matter Lesions.Journal of clinical medicine · 2025Review
- Aptamers as a New Frontier in Molecular Cancer Imaging Technologies.Chemical & biomedical imaging · 2025Review
- Noninvasive molecular imaging using anti-Trop-2 aptamer for targeted therapy of small cell lung cancer.Journal of nanobiotechnology · 2025Article
- SyntheticRSC medicinal chemistry · 2024Review
- Nucleic Acid Aptamer-Based Biosensors: A Review.Biomedicines · 2023Review
- Radiochemical Synthesis of 4-[Molecules (Basel, Switzerland) · 2022Article
- Advances in aptamer-based nuclear imaging.European journal of nuclear medicine and molecular imaging · 2022Review
- Radiolabeling of functional oligonucleotides for molecular imaging.Frontiers in bioengineering and biotechnology · 2022Review
- Revisiting the Tenascins: Exploitable as Cancer Targets?Frontiers in oncology · 2022Review
- Fluorine-18: Radiochemistry and Target-Specific PET Molecular Probes Design.Frontiers in chemistry · 2022Review
- Aptamer Applications in Neuroscience.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting.International journal of molecular sciences · 2021Review
- Article
- Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach.International journal of molecular sciences · 2021Review
- A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.Theranostics · 2021Review
- Review
- Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy.Frontiers in cell and developmental biology · 2020Review
- A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein.Molecular therapy. Nucleic acids · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
unlabelledTenascin-C is an extracellular matrix glycoprotein that is expressed by injured tissues and by various cancers. Recent publications showed that tenascin-C expression by cancer lesions predicts tumor growth, metastasis, and angiogenesis, suggesting tenascin-C as a potential therapeutic target. Currently there is no noninvasive method to determine tumoral tenascin-C expression in vivo. To address the need for an agent to image and quantify tenascin-C, we report the development of a radioactive PET tracer based on a tenascin-C-specific single-stranded DNA aptamer (tenascin-C aptamer).
methodsTenascin-C aptamer was radiolabeled with (18)F and (64)Cu. PET imaging studies for the evaluation of tumor uptake and pharmacokinetics of tenascin-C aptamer were performed in comparison to a nonspecific scrambled aptamer (Sc aptamer).
resultsThe labeled tenascin-C aptamer provided clear visualization of tenascin-C-positive but not tenascin-C-negative tumors. The uptake of tenascin-C aptamer was significantly higher than that of Sc aptamer in tenascin-C-positive tumors. The labeled tenascin-C aptamer had fast clearance from the blood and other nonspecific organs through the kidneys, resulting in high tumor contrast.
conclusionOur data suggest that suitably labeled tenascin-C aptamer can be used as a PET tracer to image tumor expression of tenascin-C with a high tumor-to-background ratio and might provide insightful and personalized medical data that will help determine appropriate treatment and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.